Phase 3 Results: Roflumilast Cream 0.15% (Zoryve, Arcutis) Hits Multiple Efficacy Endpoints in AD
Roflumilast cream 0.15% (Zoryve, Arcutis) improved atopic dermatitis (AD) across multiple efficacy endpoints while demonstrating favorable safety and tolerability, according to results from two pivotal Phase 3 studies (INTEGUMENT-1 and INTEGUMENT-2) in JAMA Dermatology. Roflumilast cream 0.15%, a once-daily, steroid-free treatment, was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the topical […]